Platform converts nonhuman antibodies into engineered human antibodies for therapeutic drug applications. KaloBios Pharmaceuticals’ granted Novartis a nonexclusive license its Humaneering™ technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results